CorMedix rises on Q2 revenue beat
CRMD•Shares rise after quarterly beat
- Shares of biopharma firm CorMedix CRMD.O rise 3.8% to $12.06 premarket
- Co reports Q2 revenue of $101.93 million, beating analysts' average estimate of $95.62 million, according to LSEG compiled data
- Co posts Q2 profit of 29 cents, vs estimates of 24 cents
- As of last close, CRMD stock was down ~39% YTD
